FREE Meningitis Vaccines – Saturday, October 22

Men’s Health Foundation will be offering FREE Meningitis vaccines regardless of whether you have health insurance. Stop by our booth at:

Sample Saturday
8578 Santa Monica Blvd (near 24 Hour Fitness)
West Hollywood, CA 90069

Saturday, Oct 22
12pm – 4pm

Los Angeles County public health officials and LGBT advocates are urging gay and bisexual men to get meningitis vaccinations, citing a recent outbreak of potentially deadly meningococcal disease that is disproportionately affecting men who have sex with men.

October 21st, 2016|Categories: Men's Health, News|

First Man to Become HIV-Positive While on PrEP is Rare Exception

After tens of thousands of PrEP successes, the first documented case of someone becoming poz includes rare multiclass drug resistance.

It’s been nearly two years since the Centers for Disease Control and Prevention issued historic guidelines recommending that thousands of Americans—particularly gay and bi men, transgender women, injection drug users, and partners of HIV-positive individuals—start taking Truvada as pre-exposure prophylaxis (or PrEP) to prevent HIV infection.

The prevention method has shown to be 99 percent effective at preventing HIV transmission among those who take it daily as prescribed and, as was reported at the Conference on Retroviruses and Opportunistic Infections this week, it’s even 86 percent effective among those using it “on demand” (essentially one dose two to 24 hours before sex, and then twice more the two days following sex).

Truvada as PrEP has had its critics from the get-go, notably Michael Weinstein, the head of AIDS Healthcare Foundation, who has led what some activists called a moral crusade against the drug. But many scientists, doctors, public health experts, and activists have heralded the prevention method as part of the necessary one-two punch needed to get HIV and AIDS numbers lowered in the U.S. (the other part being treatment as

February 29th, 2016|Categories: News|

Treatment Update Luncheon

This week, Dr. Mills spoke to a group of over 40 local HIV social workers and health care providers at the second Treatment Update Luncheon. Topics included results from the START study, latest advances in HIV treatment research, and current clinical research opportunities available through Mills Clinical Research. Stay tuned for information about future events! Dr. Mills speaking at the Treatment Update Luncheon

February 12th, 2016|Categories: News|

PrEP Toolkit

AIDS United, in partnership with the Centers of Disease Control and Prevention (CDC) and Gay Men’s Health Crisis (GMHC), has recently released their PrEP ToolKit.

This toolkit was created as a resource for staff in community-based organizations (CBOs) to support their efforts at educating communities about and increasing access to PrEP. It is divided into the following seven sections:

  1. What is PrEP?
  2. Who Is PrEP for?
  3. PrEP Research: How we know it works
  4. Kinds of PrEP
  5. Preparing your clients for PrEP
  6. PrEP cost and payment resources
  7. General PrEP resources

Various downloadable resources are linked throughout the document, including: “Questions about PrEP and the Doctor,” the “PrEP Index,” and a one-page reference of PrEP studies.

You can access the toolkit here.

January 10th, 2016|Categories: News|

Genvoya: FDA Approves New Treatment for HIV

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

The CDC estimates that 1.2 million persons ages 13 years and older are living with HIV infection, and that more than another 150,000 persons in this age range have HIV but are unaware of their infection. Over the past decade, the number of people living with HIV has increased, while the annual number of new HIV infections has remained relatively stable.

“Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

Today’s approval of a fixed dose combination containing a new form of tenofovir provides another effective, once daily complete regimen for patients with HIV-1 infection.

Genvoya is approved for use in HIV-infected adults and children ages 12 years and older weighing at least 35 kilograms (77 pounds) who have never taken HIV therapy (treatment-naïve) and HIV-infected adults

November 25th, 2015|Categories: News|